ArticleAesthetic plastic surgery2026
Efficacy and Safety of Non-Cross-Linked Sodium Hyaluronate Composite Solution Injection for Skin Condition Improvement: A Prospective, Multicenter, Randomized, Evaluator-Blinded, Blank-Controlled Superiority Trial.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMinimally invasive injectable therapies, including multi-component sodium hyaluronate composite formulations designed to improve skin quality through biological support of the dermal microenvironment, have gained increasing clinical interest, yet robust large-scale clinical evidence remains limited.
objectiveTo investigate the clinical efficacy and safety of an injectable sodium hyaluronate composite solution for improving overall skin quality and appearance.
methodsThis was a prospective, multicenter, randomized, blank-controlled, superiority clinical trial involving 561 subjects, who were randomly assigned to either the treatment group or the control group. The primary efficacy endpoint was improvement in skin appearance as evaluated by investigators using the Global Aesthetic Improvement Scale (GAIS). Secondary endpoints included multidimensional assessments of skin quality parameters as well as subject-reported satisfaction. Safety was assessed through the incidence and severity of adverse events and serious adverse events throughout the study period.
resultsThe GAIS improvement rate was markedly higher in the treatment group compared with the control group (90.00% vs. 11.90%, P < 0.0001), and this superiority was consistently observed across different analysis populations. Secondary efficacy measures further demonstrated significant improvements in skin quality and high levels of subject satisfaction in the treatment group. Most treatment-emergent adverse events were mild to moderate, transient, and localized, with no unexpected safety signals identified.
conclusionsThe injectable sodium hyaluronate composite solution demonstrated significant efficacy in enhancing skin appearance and overall skin quality, with a favorable and well-tolerated safety profile. These findings support its clinical application as a minimally invasive option for skin rejuvenation. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine Ratings, please refer to Table of Contents or online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42869969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.